PERSON
Bristol Myers’ schizophrenia drug Cobenfy stumbles as adjunctive treatment, denting blockbuster plan
Cobenfy, Schizophrenia, Antipsychotic Agents, Adjunctive Orthodontic Procedure, Myers, Statistical Significance, Improvement, Single Agent Therapy
Immunovant Refines R&D Strategy with New Leadership
Immunovant, Roivant, R&D Focus, Leadership Changes, IMVT-1402
FDA rejection of extended dosing interval is another piece of bad news for Regenerons Eylea HD
United States Food and Drug Administration, Interval, Regeneron, dosing, Extension, Eylea HD, rejection, Age related macular degeneration, Diabetic Retinopathy
FDA moves to block biopharma employees from serving on advisory committees
United States Food and Drug Administration, Workers, Advisory Committees, Industry, Policy
RFK Jr. attacks environmental toxins as cause of childhood autism ‘epidemic’, stays silent on vaccines
Autistic Disorder, Vaccines, Kennedy, Environment, RFK gene, HHS
UPDATE: With looming Trump tariffs, pharma companies demand changes to stay in EU
EU, Pharma, Industry, Transplant Registry Unified Management Program, Policy, Investments, United States, drug price
Pharma’s wins and losses in Trump’s sprawling executive order on drug prices
Medicare, Medicare, Industry, drug price, Mediation, small molecule drugs, losses, IRA, Insulin, Prices
Ayrmid misses deadline for detailed offer to top private equity bid for bluebird
Ayrmid, Family Turdidae (organism), gene therapy, Failed, Capital, proposal – intent, United States Food and Drug Administration, private equity, deadline
Trump pledges his support for a change to the IRA long sought by drugmakers
IRA, Medicare, Contraceptives, Oral, Mediation, Industry, drug price, Biological Factors, Prices, drugmakers, Medicare